期刊文献+

Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma

下载PDF
导出
摘要 BACKGROUND The role of tumor-infiltrating lymphocytes(TILs)in the growth and progression of hepatocellular carcinoma(HCC)has attracted widespread attention.AIM To evaluate the feasibility of associating liver partition and portal vein ligation for staged hepatectomy(ALPPS)for massive HCC by exploring the role of TIL in the tumor microenvironment.METHODS Fifteen massive HCC patients who underwent ALPPS treatment and 46 who underwent hemi-hepatectomy were selected for this study.Propensity score matching was utilized to match patients in ALPPS and hemi-hepatectomy groups(1:1).Quantitative analysis of TILs in tumor and adjacent tissues between the two groups was performed by immunofluorescence staining and further analyses with oncological characteristics.In the meantime,trends of TILs in peripheral blood RESULTS Continuous measurement of tumor volume and necrosis volume showed that the proportion of tumor necrosis volume on the seventh day after stage-I ALPPS was significantly higher than the pre-operative value(P=0.024).In the preoperative period of stage-I ALPPS,the proportion of tumor necrosis volume in the high CD8+T cell infiltration group was significantly higher than that in the low group(P=0.048).CONCLUSION TIL infiltration level maintained a dynamic balance during the preoperative period of ALPPS.Compared with right hemi-hepatectomy,the ALPPS procedure does not cause severe immunosuppression with the decrease in TIL infiltration and pathological changes in immune components of peripheral blood.Our results suggested that ALPPS is safe and feasible for treating massive HCC from the perspective of immunology.In addition,high CD8+T cell infiltration is associated with increasing tumor necrosis in the perioperative period of ALPPS.
出处 《World Journal of Gastrointestinal Surgery》 SCIE 2022年第9期1008-1025,共18页 世界胃肠外科杂志(英文版)(电子版)
基金 Supported by the National Natural Science Foundation of China,No.8190111624 Guangxi Natural Science Foundation of China,No.2018JJB140382 Guangxi University Young and Middle-Aged Teachers’Basic Scientific Research Ability Improvement Project,No.2019KY0123.
  • 相关文献

参考文献4

二级参考文献29

  • 1[23]Adachi E,Matsumata T,Nishizaki T,Hashimoto H,Tsuneyoshi M,Sugimachi K.Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma.The relationship between postoperative course and tumor necrosis.Cancer 1993; 72:3593-3598
  • 2[24]Yamakado K,Nakatsuka A,Tanaka N,Matsumura K,Takase K,Takeda K.Long-term follow-up arterial chemoembolization combined with transportal ethanol injection used to treat hepatocellular carcinoma.J Vasc Interv Radiol 1999; 10:641-647
  • 3[25]Georgiades CS,Hong K,D'Angelo M,Geschwind JF.Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.J Vasc Interv Radiol 2005; 16:1653-1659
  • 4[1]Bruix J,Llovet JM.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology 2002; 35:519-524
  • 5[2]Trinchet JC,Beaugrand M.Treatment of hepatocellular carcinoma in patients with cirrhosis.J Hepatol 1997; 27:756-765
  • 6[3]Bruix J,Sherman M,Llovet JM,Beaugrand M,Lencioni R,Burroughs AK,Christensen E,Pagliaro L,Colombo M,Rodes J.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver.J Hepatol 2001; 35:421-430
  • 7[4]Lai EC,Fan ST,Lo CM,Chu KM,Liu CL,Wong J.Hepatic resection for hepatocellular carcinoma.An audit of 343 patients.Ann Surg 1995; 221:291-298
  • 8[5]Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma.Lancet 2003; 362:1907-1917
  • 9[6]Fan ST.Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy.Hepatogastroenterology 2002; 49:17-20
  • 10[7]Makuuchi M,Belghiti J,Belli G,Fan ST,Lau JW,Ringe B,Strasberg SM,Vauthey JN,Yamaoka Y,Yamasaki S.IHPBA concordant classification of primary liver cancer:working group report.J Hepatobiliary Pancreat Surg 2003; 10:26-30

共引文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部